INFY: security and annual income

PERALTA FACTUAL EXTRACTION - verify against original filing

Security - cover and Item 9

NYSE ticker INFY. One American Depositary Share represents one equity share.
Fiscal year ends March 31. IFRS figures below are USD millions, except per share.

Item 18, consolidated statement of comprehensive income, years FY2024/FY2025/FY2026

Revenue: 18,562 / 19,277 / 20,158.
Operating profit: 3,834 / 4,071 / 4,085.
Net profit: 3,169 / 3,162 / 3,316.
Diluted EPS (USD): 0.76 / 0.76 / 0.80.
FY2026 diluted weighted shares: 4,120,108,168.

Item 5 and note 2.20: FY2026 segment revenue and operating profit

Financial Services: revenue 5,631; segment profit 1,427.
Manufacturing: revenue 3,282; segment profit 726.
Energy, Utilities, Resources and Services: revenue 2,688; segment profit 675.
Retail: revenue 2,605; segment profit 799.
Communication: revenue 2,455; segment profit 434.
Hi-Tech: revenue 1,572; segment profit 363.
Life Sciences: revenue 1,383; segment profit 276.
Other: revenue 542; segment profit 80.
Total segment revenue 20,158; segment profit 4,780; unallocable expenses 695; EBIT 4,085.

INFY: annual cash and claims

PERALTA FACTUAL EXTRACTION - verify against original filing

Item 18, consolidated cash flow, years FY2024/FY2025/FY2026; USD millions

Operating cash flow: 3,148 / 4,351 / 4,039.
Capital expenditure net of sale proceeds: 266 / 263 / 306.
Lease liability payments: 245 / 278 / 318.
Dividends paid: 1,777 / 2,416 / 2,133.
FY2026 equity share buyback including costs: 2,006.
FY2026 operating cash less capital expenditure less lease payments: 3,415 (Peralta calculation).

Item 18, balance sheet March 31 2026; USD millions

Cash 2,341; current investments 1,365; noncurrent investments 942.
Current lease liabilities 333; noncurrent lease liabilities 634.
Total assets 16,446; total liabilities 6,606; NCI 54.
Net equity shares at March 31 2026: 4,046,940,812.

Item 12, ADS charges

Depositary cash distribution fee up to USD 0.01 per ADS per distribution.
Depositary administrative services fee up to USD 0.02 per ADS per calendar year.

INFY: September 2026 interim

PERALTA FACTUAL EXTRACTION - verify against original filing

IFRS USD audited six months ended September 30 2026 versus 2025; USD millions

Revenue 10,227 versus 10,018; operating profit 2,151 versus 2,093.
Net profit 1,639 versus 1,649; diluted weighted shares 4,054,149,523.
Operating cash flow 2,050 versus 2,140; capex 167 versus 155.
Lease liability payments 191 versus 159; dividends paid 1,070 versus 1,063.
Business acquisitions net of cash acquired 340 versus 76.

IFRS USD balance sheet September 30 2026; USD millions

Cash 2,541; current investments 1,436; noncurrent investments 875.
Current lease liabilities 374; noncurrent lease liabilities 516.
Total assets 17,060; total liabilities 6,671; NCI 56.
Net equity shares at September 30 2026: 4,050,360,983.
Post-balance interim dividend INR 26/share; estimated total cash outflow USD 1,099 million, note 2.1 8.

Peralta trailing twelve months to September 30 2026; USD millions

Revenue 20,367 = FY2026 20,158 + H1 10,227 - prior H1 10,018.
EBIT 4,143 = FY2026 4,085 + H1 2,151 - prior H1 2,093.
CFO 3,949; capex 318; lease payments 350; cash after both 3,281.

INFY: operating evidence and ownership

PERALTA FACTUAL EXTRACTION - verify against original filing

6-K press release October 23 2026

FY2027 constant-currency revenue growth guidance: 1% to 2%.
FY2027 operating margin guidance: 20% to 22%.
Q2 FY2027 revenue USD 5,145 million; operating margin 21.0%.
Q2 FY2027 large-deal TCV USD 5.2 billion; 62% net new.
Interim dividend record November 3 2026; scheduled payment November 11 2026, 6-K exhibit 99.6.

6-K fact sheet, FY2027 H1 segment revenue; USD millions

Financial Services 2,858; Manufacturing 1,635; Energy/Utilities/Resources/Services 1,409.
Retail 1,243; Communication 1,253; Life Sciences 838; Hi-Tech 739; Other 252.
Total H1 FY2027 revenue 10,227; segment profit 2,424; unallocable 273; EBIT 2,151.
Cash and investments per issuer liquidity presentation: USD 4,720 million at Sep 30 2026.

FY2026 20-F, Item 7 beneficial holders at May 20 2026

Life Insurance Corporation of India: 438,350,372 shares, 10.81%.
Nandan M. Nilekani incl. immediate family: 100,461,168 shares, 2.48%.
All directors and executive officers: 102,731,292 shares, 2.53%.
Item 7 denominator: 4,056,360,091 equity shares.